Subtitle
Selection of Mediastinal Lymphoma Patients for Proton Therapy Within the Proton Collaborative Group Registry: Concordance With the ILROG Guidelines.
Subtitle
Selection of Mediastinal Lymphoma Patients for Proton Therapy Within the Proton Collaborative Group Registry: Concordance With the ILROG Guidelines.
Proto therapy Time
June 20221
Executive summary
This study reviewed 56 mediastinal lymphoma patients treated with proton therapy and reported that nearly all treated patients fit the International Lymphoma Radiation Oncology Group consensus recommendations published in 2018 regarding which mediastinal lymphoma patients may most benefit from proton therapy. Mediastinal lymphoma patients treated with proton therapy are typically young with lower mediastinal involvement.
Top cancer treatments
Related contents
Proton Therapy Publication
April 2024
A bibliometric analysis of cardiotoxicity in cancer radiotherapy.
Proton Therapy Publication
March 2024
Evidence for external beam radiotherapy in mediastinal Hodgkin and non-Hodgkin lymphoma - systematic review.
Proton Therapy Publication
May 2023
Outcomes of Patients Treated in the UK Proton Overseas Programme: Non-central Nervous System Group.
Proton Therapy Publication
December 2022
Proton and Carbon Ion Radiotherapy Decreased Severe Lymphopenia by Reducing Thoracic Vertebra and Aortic Dose in Non-small Cell Lung Cancer versus Intensity Modulated Radiotherapy.
Proton Therapy Publication
October 2022
Systematic Review for Deep Inspiration Breath Hold in Proton Therapy for Mediastinal Lymphoma: A PTCOG Lymphoma Subcommittee Report and Recommendations.
Proton Therapy Publication
August 2021
Establishing cost-effective allocation of proton therapy for patients with mediastinal Hodgkin lymphoma
Proton Therapy Publication
July 2021
Current Situation of Proton Therapy for Hodgkin Lymphoma: From Expectations to Evidence
Proton Therapy Publication
April 2021
Comparing second cancer risk for multiple radiotherapy modalities in survivors of Hodgkin lymphoma
Proton Therapy Publication
January 2021
Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory lymphoma: A PTCOG and PCG Collaboration.